Tibet Duo Rui Pharmaceutical Co.Ltd.
Tibet Duo Rui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, intermediates, and raw materials in China. It offers fluid therapy, anesthesiology medication, analgesic medication, and first-aid medication products, as well as sodium acetate ringer's injection; and agent products, such as amoxicillin sodium and clavulan… Read more
Tibet Duo Rui Pharmaceutical Co.Ltd. (301075) - Total Liabilities
Latest total liabilities as of June 2025: CN¥754.44 Million CNY
Based on the latest financial reports, Tibet Duo Rui Pharmaceutical Co.Ltd. (301075) has total liabilities worth CN¥754.44 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tibet Duo Rui Pharmaceutical Co.Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how Tibet Duo Rui Pharmaceutical Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tibet Duo Rui Pharmaceutical Co.Ltd. Competitors by Total Liabilities
The table below lists competitors of Tibet Duo Rui Pharmaceutical Co.Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Santa Cruz County Bank
OTCQX:SCZC
|
USA | $2.31 Billion |
|
Guangzhou Echom Sci&Tech Co Ltd
SHE:002420
|
China | CN¥1.87 Billion |
|
ITI Limited
NSE:ITI
|
India | ₹89.25 Billion |
|
X4 Pharmaceuticals Inc
NASDAQ:XFOR
|
USA | $101.94 Million |
|
LDR Turizm AS
IS:LIDER
|
Turkey | TL3.37 Billion |
|
Ascencio (D)
BR:ASCE
|
Belgium | €323.38 Million |
|
Wabash National Corporation
NYSE:WNC
|
USA | $802.70 Million |
|
Daesang Corp
KO:001680
|
Korea | ₩2.04 Trillion |
Liability Composition Analysis (2019–2024)
This chart breaks down Tibet Duo Rui Pharmaceutical Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tibet Duo Rui Pharmaceutical Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tibet Duo Rui Pharmaceutical Co.Ltd. (2019–2024)
The table below shows the annual total liabilities of Tibet Duo Rui Pharmaceutical Co.Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥781.52 Million | +211.87% |
| 2023-12-31 | CN¥250.59 Million | +72.28% |
| 2022-12-31 | CN¥145.45 Million | +131.65% |
| 2021-12-31 | CN¥62.79 Million | -52.52% |
| 2020-12-31 | CN¥132.25 Million | -8.25% |
| 2019-12-31 | CN¥144.14 Million | -- |